Pure Global
NCT06416800

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics When Administered Orally to Healthy Adult Participants

An Open-Label Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics When Administered Orally to Healthy Adult Participants
Incyte Corporation·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
Digoxin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Incyte Corporation
Location
Dallas, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Jun 19, 2024
End date
Aug 10, 2024
Enrollment
54 participants
Primary outcome

Pharmacokinetic (PK) in plasma digoxin,PK in plasma rosuvastatin,PK in plasma metformin

Summary

The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin,
 and Metformin Pharmacokinetics When Administered Orally to Healthy Adult Participants.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06416800
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06416800 through Pure Global AI's free database. This Phase 1 trial is sponsored by Incyte Corporation and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 54 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.